High-Glucose High-Fat Culture Conditions
The numbers, in context
| Condition | Concentration | Compared with plasma |
|---|---|---|
| Plasma, fasting | 4.4–5.0 mM | Reference |
| Plasma, postprandial | 6–8 mM | Reference |
| Diabetes, poor control | 8–15 mM | 2–3× fasting |
| RPMI 1640 | 11.1 mM | 2× fasting |
| DMEM, low glucose | 5.6 mM | Near fasting |
| DMEM, high glucose | 25 mM | 5× fasting |
| "High glucose" in most papers | 25–30 mM | 5–6× fasting |
Two consequences follow. First, cells grown in RPMI are already in a hyperglycaemic medium, so a "normal glucose" control at 11 mM is not normal. Second, a "high glucose" condition at 25 mM is above anything a patient reaches, including in diabetic ketoacidosis, where values are high but not sustained for days in every tissue.
Important distinction. A supraphysiological stimulus can be a legitimate tool — it produces a robust, reproducible phenotype. It is not a model of diabetes. The claim should say which it is.
Osmotic control
Glucose at 25 mM adds roughly 25 mOsm, which is a real osmotic load on a cell.
| Control | Osmolarity matched | Valid | Note |
|---|---|---|---|
| Mannitol, 25 mM | Yes | Yes | Standard choice |
| L-glucose, 25 mM | Yes | Yes | Not metabolised; expensive |
| NaCl, 25 mM | Yes | Yes | Changes ionic strength; acceptable |
| None | No | No | The effect is unattributable |
The control is absent in a large fraction of published high-glucose experiments. Without it, an effect can be osmotic, and osmotic stress activates overlapping signalling with metabolic stress — including NF-κB, p38 and cell-cycle arrest.
Caveat on mannitol. Mannitol is not always inert: it is taken up slowly by some cells and can affect organic osmolyte handling. L-glucose is the cleaner control but costs more. Either is better than none.
Fatty acids are not a diet
| Feature of a high-fat diet | Present in culture |
|---|---|
| Excess energy intake | No |
| Adipose storage and release | No |
| Chylomicron and lipoprotein transport | No |
| Gut-derived signals (GLP-1, bile acids) | No |
| Systemic insulin response | No |
| Elevated fatty acid supply to the cell | Yes, as BSA-bound supplement |
A culture condition with 200 µM palmitate delivers fatty acids to a cell. A high-fat diet delivers fatty acids, changes adipose function, alters enteroendocrine signalling and produces hyperinsulinaemia. The two share one variable out of several, and "high-fat culture model" implies more than it delivers.
Important distinction. What a fatty acid supplement models is substrate supply to a cell, which is the relevant variable for lipotoxicity, ER stress and lipid droplet formation. It is not the relevant variable for insulin resistance as a systemic phenomenon.
Composition of the fat
| Supplement | Receptor/route | Outcome |
|---|---|---|
| Palmitate (C16:0) | TLR4, ER stress, ceramide | Injury, inflammation |
| Oleate (C18:1) | Esterification | Storage, protection against palmitate |
| Linoleate (C18:2) | Oxidation-prone | Lipid peroxidation, ferroptosis sensitisation |
| Mixed (commercial lipid mix) | Multiple | Reproducible but undefined |
| Lipoprotein-derived cholesterol | LDLR | Foam cell formation, cholesterol crystal |
Saturated and unsaturated fatty acids are not interchangeable, and a "high-fat" condition should specify the species. The oleate:palmitate ratio is the single most informative parameter, as it is in the hepatocyte steatosis model.
Duration and adaptation
| Duration | What is being measured |
|---|---|
| 1–6 h | Acute signalling and biophysics |
| 24–48 h | Transcriptional adaptation, lipid accumulation |
| 72 h–1 week | Selection; the surviving population is different |
| > 1 week | Clonal adaptation, not a response |
Caveat on long exposures. Any condition that reduces proliferation produces a population selected for tolerance. After two weeks at 25 mM glucose, the cells that remain are not "adapted cells" in a physiological sense; they are the minority that grew. Distinguishing adaptation from selection requires a washout and recovery arm, or a proliferation-matched control.
Combined glucolipid conditions
| Design | Tests | Confound |
|---|---|---|
| High glucose alone | Hexosamine, osmotic, methylglyoxal effects | Missing lipogenic substrate |
| Palmitate alone | Lipid-mediated stress | Missing insulin and glucose drive |
| High glucose + high insulin | Lipogenic induction | Insulin desensitisation |
| High glucose + palmitate | Glucolipotoxicity | Attribution impossible |
| All three | The in vivo loop | Attribution impossible, and no single-variable control |
The second and third rows are useful because they isolate a mechanism. The fifth is the closest to the disease and the least able to say what caused what. Run the isolated arms alongside it if attribution is the claim.
Readout note. Ammonia and osmolarity should be measured in long high-glucose cultures: glutamine degrades spontaneously in medium at 37 °C, and the resulting ammonia contributes to the phenotype independently of glucose. A glucose-only interpretation of a 72-hour experiment is incomplete without it.
Failures that recur
- • No osmotic control. The most common omission in this literature.
- • "Normal glucose" control at 11 mM. That is already above plasma.
- • Supraphysiological condition described as a disease model.
- • Fatty acid species unstated. Palmitate and oleate do opposite things.
- • BSA ratio unstated, so free concentration is unknown.
- • Long exposure read as adaptation. It is selection.
- • Ammonia not measured in multi-day cultures.
- • Insulin concentration unstated in glucolipid protocols.
Where this connects
- • Insulin resistance models article supplies the interpretation of what each combination produces.
- • MASH cell models article supplies the fatty acid ratio logic for hepatocytes.
- • Amino acid pillar supplies the glutamine degradation and ammonia problem in aged medium.
- • Disease pillar supplies the frame: a culture condition is one variable, a disease is several.
Scientific interpretation and experimental design
- • State the concentration and the plasma comparison.
- • Run an osmotic control. Mannitol or L-glucose.
- • Do not call it a disease model. Call it a stimulus.
- • Specify the fatty acid species. Ratio matters more than total.
- • Report BSA molar ratio.
- • Keep exposures short enough to be a response, not a selection.
- • Measure ammonia and osmolarity in long cultures.
Selected references for further reading
- • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
- • Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790.
- • Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS. 2003;100:3077–3082.
- • Tritsch GL, Moore GE. Spontaneous decomposition of glutamine in cell culture media. Experimental Cell Research. 1962;28:360–364.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »